Opioid Conversions Mixture of Science and Art
|
|
- Rosa Sullivan
- 6 years ago
- Views:
Transcription
1 Opioid Conversions Mixture of Science and Art Matthew J. Pingree, MD Assistant Professor Division of Pain Medicine Physical Medicine and Rehabilitation and Anesthesiology Mayo Clinic, Rochester Pain Medicine for the Non-Pain Specialist February 16-18, MFMER slide-1
2 Disclosure of Financial Relationships Matthew J. Pingree MD Has no relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients MFMER slide-2
3 Objectives Brief Review of important information regarding some newer opiates Explain the appropriate use of the Equianalgesic Opioid Dosing Chart and limitations Understand the steps to complete and what to consider when changing opioid medication Review some sample cases that highlight important points 2016 MFMER slide-3
4 Opioid Responsiveness Degree of analgesia achieved as dose escalated Potency Intensity of analgesic effect for a given dose Access to the receptor Binding Affinity Physiochemistry Physical and chemical process of binding to a receptor 2016 MFMER slide-4
5 Pharmacokinetics What the body does to the drug Absorb Distribute - Metabolize - Excrete Equianalgesic Doses of drug or route that provide the same degree of relief Bioavailaibilty % drug detected in circulation and available to provide relief IV drug = 100% bioavailable! Morphine 30-40% - Hydromorphone 50% Oxycodone 80% - Oxymrophone 10% 2016 MFMER slide-5
6 2016 MFMER slide-6
7 The Equianalgesic Table (Simplified) PO IV/SQ Relative Potency Morphine 30 mg 10 mg 1:3 Oxycodone 20 mg N/A -- Hydromorphone 7.5 mg 1.5 mg 1:5 Fentanyl N/A 100 mcg -- Oxymorphone 10 mg 1 mg 1:10 McPherson, ML Demystifying opioid conversion calculations MFMER slide-7
8 Tapentadol MOA Mu receptor agonist, NERI, Weak SSRI Indication Mod - Severe Acute pain >18 years of age Formulation IR 50mg, 75mg, 100mg q 4-6 hours No published data on conversion less potent than morphine (suggested) Tapentadol 50 mg q4-6 -> Oxycodone 5mg Tapentadol 75 mg q4-6 -> Oxycodone 10mg Tapentadol 100 mg q4-6 -> Oxycodone 15mg 2016 MFMER slide-8
9 Buprenorphine ( ) Brief Facts for Conversions: OME <30 mg/day -> 5 mcg/hr OME >30-80 mg/day - > 10 mcg/hr Potential withdrawal when switching Oral Morphine to TD 1mg:75 mcg Conservative estimate Breakthrough meds should be anticipated MFMER slide-9
10 Extended Release Hydromorphone (Exalgo) Once Daily Moderate to severe chronic pain Not acute pain Only opioid tolerant 3 days to steady state do not change dose IR to LA use equivalent daily dose Breakthrough dose of 10-15% 2016 MFMER slide-10
11 Abuse Deterrent Formulations DO NOT affect the conversion calculations! reformulated to release all at once Kadian now Core of each bead contains naltrexone Cut crushed or chewed negates effect Currently not available in US IR oxycodone tablet Ingredient causes drug to gel 2016 MFMER slide-11
12 Careful with the Chart! Source of the Data Single dose in Naïve patients Patient Variability Genetic polymorphism Organ function Age/Sex Unidirectional vs. Bidirectional Morphine to Hydromorphone (5-8:1) not the same as Hydromorphone to Morphine (1:3-4) 2016 MFMER slide-12
13 Why Change? 1. Lack of response Disease progression Tolerance Adverse effects Combination drug exceeds maximum 2. Development of Adverse Effects (Later w/ Dr. Feely) 1. GI 2. Autonomic (urinary retention..) 3. Cutaneous 4. CNS 5. Allergy 2016 MFMER slide-13
14 Why Change? 3. Change in Patient Status Cannot Swallow PO to IV 4. Other Cost Availability Beliefs/Prior experience 2016 MFMER slide-14
15 Extended-release/longacting(ER/LA) opioid: Increased risk of nonfatal overdose. Greatest in the first 2 weeks. ER/LA opioids found no clear differences related to pain or function Special Communication CDC Guideline for Prescribing Opioids for Chronic Pain United States, 2016 Deborah Dowell, MD, MPH; Tamara M. Haegerich, PhD; Roger Chou, MD 2016 MFMER slide-15
16 Recommendation about Selection, Dosage, Follow-Up and Discontinuation 1. Immediate-release opioids to initiate therapy 2. Start with the lowest effective dosage 3. For acute pain, use for least amount of time 3 days or less and not usually more than 7 days. 4. Evaluate benefits and harms in 1 to 4 weeks. Special Communication CDC Guideline for Prescribing Opioids for Chronic Pain United States, 2016 Deborah Dowell, MD, MPH; Tamara M. Haegerich, PhD; Roger Chou, MD 2016 MFMER slide-16
17 5 Steps of Opioid Conversion 1. Assess the patient (PQRSTU) 2. Determine Total Daily Dose 3. Decide on new agent Consult Equianalgesic Table 4. Individualize dosage based on current situation 5. Follow-up and reassessment 2016 MFMER slide-17
18 5 Steps of Opioid Conversion 1. Assess the patient (PQRSTU) Precipitating and Palliating Breakthrough analgesics? Quality stabbing, shooting Region and Radiation deep/superficial Severity Best and worst Temporal constant, come/go U how is it affecting YOU- sleep, appetite MFMER slide-18
19 5 Steps of Opioid Conversion 2. Total Daily Dosage (TDD) Complete list and how the patient is actually taking the medicine Long and short acting included Opportunities for patient education Remember all routes of administration 3. Decide on new medication Can they swallow? Renal function Type of pain Availability Drug interactions Calculate new dose 2016 MFMER slide-19
20 5 Steps of Opioid Conversion 1. Calculate the current daily dose 2. Set up conversion ratio of current opioid to new opioid X mg new opioid/route x equivalent dose new opioid/route mg current opioid/route equivalent dose current opioid/route X mg hydromorphone/po x 7.5 mg Hydromorphone/PO 90 mg morphine/po 30 mg morphine /PO (X)(30) =(90)(7.5) (X) = 22.5 mg hydromorphone/po per day 2016 MFMER slide-20
21 5 Steps of Opioid Conversion 4. Individualize to the patient Decrease Adverse effects Incomplete cross-tolerance Same Pain not controlled Increase Severe pain or crisis Route: Home alone? Hospitalized? SNF? Dosing Frequency Account for residual medicine during transition Trust your gut! 2016 MFMER slide-21
22 5 Steps of Opioid Conversion 5. Monitoring the patient Pain rating Sleep? More functional? Adverse effects Sedation Pupils Respiratory rate Cognition 2016 MFMER slide-22
23 Case #1 JP 62 yo M with Multiple Myeloma and diffuse bony metastasis Morphine ER 30 BID Morphine IR Liquid 10 mg every 2 hours Using about 5x s Senna Dexamethasone 4 mg BID Temazapam 15 mg QHS Lorazapam 1 mg PO Q4 Pain is 5-7/10 not controlled 2016 MFMER slide-23
24 Case #1 JP 62 yo M with Multiple Myeloma and diffuse bony metastasis Step 1 - Assess Anxious, fearful, Deep/aching, Continuous with acute worsening Step 2 TDD 30 mg ER Tabs BID x 2 = 60 mg 10 mg IR Liquid 5 x = 50 mg TDD = 110 mg morphine per day 2016 MFMER slide-24
25 Case #1 Step 3 Calculate starting dose of IV Morphine TDD x 10 mg IV/30 mg PO = TDD New 110 x 1/3 = 36.7 mg = TDD IV Morphine Step 4 Individualize Increase dose due to poor control No cross tolerance 25-50% increase appropriate 0.25 x 36.7 = mg increase = mg new TDD Q4 hour dosing = / 6 doses = MFMER slide-25
26 Case #1 7.5 mg IV Morphine Q4 hours When do you give the first IV dose? Last dose of LA 7 hours ago Last dose of IR 3 hours Pain is increasing IV dose NOW! 2016 MFMER slide-26
27 Case #1 Step 5: Monitor and Follow-up Reassess minutes IV morphine 5 minutes onset minutes peak hours to steady state No relief 25-50% increase 10 mg Q 4 hours 2016 MFMER slide-27
28 Case #2 DT 62 yo F recent bowel surgery. 12mg IV Hydromorphone/24 hours Good pain control what to go home on? Step1: TDD = 12 mg ID Hydromorphone Step 2: Equivalent dose 12 mg IV x 7.5 mg PO/1.5 mg IV = 60 mg PO Hydromorphone per day 60 mg PO Hydromorphone 20 mg Oxycodone/7.5 Hydromorphone = 160 mg Oxycodone per day 2016 MFMER slide-28
29 Case #2 Pain is currently well controlled and expected to decrease 25-50% reduction TDD Option # mg Q4 = mg IR Option #2 40 mg BID ER, 5-10 mg IR Q4 = mg Cross tolerance? 2016 MFMER slide-29
30 Case #3 TC 45 yo M with lung cancer pain has been increasing over the past several weeks Percocet 10/325 6 tablets/day Continuous increasing pain. Not well controlled. Lost his insurance - Morphine. Step 2: TDD = 60 mg Oxycodone 2016 MFMER slide-30
31 Case #3 60 mg Oxycodone x 30 Morphine/20 Oxycodone = 90 mg Morphine Pain is not controlled 25-50% increase New TDD with increase = 60 mg Morphine ER 30 mg BID 15 mg IR Oxycodone Q4 hours PRN 2016 MFMER slide-31
32 Case #4 KG 52 yo woman with chronic pain and significant nausea with oral pain medication Current: TDF 25 mcg/h 20 mg PO BID Hydromorphone 4 mg Q4h 6/day Calculate TDD (w/o TDF): 40 mg Oxycodone x 30 mg Morphine/20 mg Oxycodone = 60 mg PO morphine 24 mg Hydromorphone x 30 mg morphine/7.5 mg hydromorphone = 96 mg Morphine TDD (w/o TDF) = 156 mg OME 2016 MFMER slide-32
33 Converting to TDF 1. Determine OME 2. Use conversion of 2:1 (mg oral morphine per DAY to mcg/hr) 3. Round up or down based on: Patch Strength Pain Level Overall Clinical Status 156 OME x 1 mcg Hr TD Fentanyl/2 mg OME Day = 78 mcg/hr --> 75 mcg patch 25 mcg/hr TD Patch + 75 mcg/hr TD patch = 100 mcg/hr TD patch Beitbart W.,et al., Oncology, MFMER slide-33
34 Case #4 How do we implement our plan? Option 1: Place 100 mcg patch at time of last Dose 100 mcg/hr = 200 mg OME/day 10-15% for breakthrough = mg mg PR Option 2: Place 100 mcg patch at time of last Dose 200 OME x 7.5 mg Hydromorphone/30 Morphine = 50 mg PO Hydromorphone 50 mg PO Hydromorphone x 1.5 IV/7.5 PO = 10 mg IV Hydromorphone/Day mg IV Hydromorphone q 4 hours 2016 MFMER slide-34
35 Case #4 Timing information Add 75 mcg now or take off 25 mcg and replace with 100 mcg/hr patch 12 hours to see clinically meaningful increase At least 36 hours to achieve maximum steady state 2016 MFMER slide-35
36 Transdermal Fentanyl Common Mistakes: Acute pain Intermittent or mild pain Not opioid tolerant Following for >1 week 60 morphine 25 mcg/hr TDF 30 mg Oxycodone 8 mg hydromorphone 25 mg oxymorphone 17 hours after removal 50% Fentanyl is eliminated from body 2016 MFMER slide-36
37 Fentanyl Rapid Acting All for opioid tolerant Cancer Pain Start with lowest dose and titrate Fentanyl lozenge Buccal Tablet (Fentora) Buccal soluble film (Onsolis) Sublingual tablet (Abstral) Nasal Spray (Lazanda) 2016 MFMER slide-37
38 Drug Conversion Conclusions 1. Be aware and alert as to when clinical scenario may dictate a change 2. Understand Principles associated with changing (responsiveness, potency, etc.) 3. Use five step conversion process 4. Use a fair and balanced equianalgesic dosing chart understand limitations 5. Consider the timing of the switch 6. Document and educate 2016 MFMER slide-38
39 Mayo Clinic Locations 2016 MFMER slide-39
40 Questions & Discussion 2016 MFMER slide-40
Fighting the Good Fight: How to Convert Opioids Just Right!
Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,
More informationOpioid Case Studies. Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN. September 29, MFMER slide-1
Opioid Case Studies Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN September 29, 2016 2015 MFMER slide-1 Disclosures Relevant Financial Relationship(s) None Off Label and/or
More informationB. Long-acting/Extended-release Opioids
4 Opioid tolerance is assumed in patients already taking fentanyl 25 mcg/hr OR daily doses of the following oral agents for 1 week: 60 mg oral morphine, 30 mg oxycodone, 8 mg hydromorphone, 25 mg of oxymorphone
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More informationDrug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans
FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA
More informationEducation Program for Prescribers and Pharmacists
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under this Program Abstral (fentanyl)
More informationSession II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids
Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be
More informationOpioid Pearls and Acute Pain Management
Opioid Pearls and Acute Pain Management Jeanie Youngwerth, MD University of Colorado Denver Assistant Professor of Medicine, Hospitalist Associate Director, Colorado Palliative Medicine Fellowship Program
More informationPharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More information10 mg hydrocodone equals how much oxycodone
Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)
More informationOpioid Use in Serious Illness
Opioid Use in Serious Illness Jeanie Youngwerth, MD University of Colorado School of Medicine Associate Professor of Medicine, Hospitalist Director, Palliative Care Service Associate Director, Colorado
More informationORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA
ORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: Fentanyl by oral transmucosal and nasal delivery Actiq (fentanyl citrate) lozenge on a handle 200,
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationNATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND
Coverage of drugs is first determined by the member s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document I. FDA Approved Indications: The management of breakthrough
More informationLong Term Care Formulary HCD - 08
1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationAmber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center
Pharmacologic Management of Pain Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center Objectives Identify types of
More informationMEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111
POLICY: Medicare Part D Formulary-Level Cumulative Opioid and Opioid/Buprenorphine POS Edits MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 Policy for contracts H3351, S3521 and H3335
More informationLimitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.21 Subject: Subsys Page: 1 of 5 Last Review Date March 17, 2017 Subsys Description Subsys (fentanyl
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl
More informationEmbeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 6 Last Review Date: March 18, 2016 Embeda Description Embeda (morphine
More informationInterprofessional Webinar Series
Interprofessional Webinar Series Opioids in the Medically Ill: Principles of Administration Russell K. Portenoy, MD Chief Medical Officer MJHS Hospice and Palliative Care Director MJHS Institute for Innovation
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and
More informationSession VI. Presenter Disclosure Information. Learning Objectives for Session VI. Prescribing Information. Prescribers Must Be Knowledgeable
SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4 6pm SPEAKERS Charles Argoff, MD, FABPM Michael Brennan, MD, FACP, FASAM Jeffrey Gudin, MD Presenter Disclosure Information The
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.CPA.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder
More informationPALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST
PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST TREATMENT IN ONCOLOGY Main treatment : surgery Neoadjuvant treatment : RT, CMT Adjuvant treatment : Tx micrometastatic disease -CMT,Targeted
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Transmucosal Fentanyl Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 1018 Table of Contents Coverage Policy... 1 General
More informationBlueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
More informationPain management. Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD
Pain management Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD Case #1 61 yo man with history of Stage 3 colon cancer, s/p resection and adjuvant chemotherapy with FOLFOX
More informationTransmucosal Immediate Release Fentanyl (TIRF) Prior Authorization, (Through Generic), and Quantity Limit Program Summary
Transmucosal Immediate Release Fentanyl (TIRF) Prior Authorization, (Through Generic), and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-5 Drug Indication Dosage Abstral (fentanyl sublingual
More informationPharmacologic Considerations for Managing Sickle Cell Pain Claire Saadeh, PharmD, BCOP May 5, 2015
Pharmacologic Considerations for Managing Sickle Cell Pain Claire Saadeh, PharmD, BCOP May 5, 2015 Table 1: Physiologic changes that occur during sickle cell pain crisis 1-3 Phase Description / Complications
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationEXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
More informationClinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid
Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationEquianalgesic Dosing: Making Opioid Interchange Easier. Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine
Equianalgesic Dosing: Making Opioid Interchange Easier Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine 1 Why Change Opioids? Side Effects Insufficient Pain
More informationAcute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX
Acute Pain Management in the Hospital Setting Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX 2 What is Pain? An unpleasant sensory and emotional experience associated
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.HNMC.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More information15mg oxycodone is equivalent to how much morphine
15mg oxycodone is equivalent to how much morphine The Borg System is 100 % 15mg oxycodone is equivalent to how much morphine nursing home activity director cover letter 15 mg oxycodone equal to how much
More informationOAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM
OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian
More informationPAIN MANAGEMENT PGY-1. Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC
PAIN MANAGEMENT PGY-1 Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC Perception Matters A builder aged 29 came to the accident and emergency
More informationER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care
ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care In August 2014, the Food and Drug Administration (FDA) updated the Extended- Release/Long Acting Opioids REMS Blueprint (BP). CO*RE has
More informationTo Infinity and Beyond! Safe and Effective Opioid Titration Strategies
To Infinity and Beyond! Safe and Effective Opioid Titration Strategies Alexandra L. McPherson, PharmD, MPH Slide development Mary Lynn McPherson, PharmD, MA, BCPS, CPE Professor and Executive Director,
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Topic: fentanyl-containing medications: - Actiq, fentanyl citrate oral transmucosal lozenges - Abstral fentanyl sublingual tablets - Fentora, fentanyl buccal tablet - fentanyl
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationObjectives. Patient Controlled Analgesia (PCA) Management in the Seriously Ill. Discuss principles for opioid dosing and titration for acute pain
Patient Controlled Analgesia (PCA) Management in the Seriously Ill Jeanie Youngwerth, MD University of Colorado School of Medicine Associate Professor of Medicine, Hospitalist Associate Director, Colorado
More informationConvert hydrocodone to ms contin
Convert hydrocodone to ms contin The Borg System is 100 % Convert hydrocodone to ms contin Jan 29, 2018. HYDROcodone (Vicodin, Lortab), -, 30-45 mg, -, 3-5. OXYmorphone (Opana), 1 mg, 10 mg, 10:1, 3-6.
More information1/21/14. Cancer Related Pain: Case-Based Pharmacology. Conflicts of Interest. Learning Objective
Cancer Related Pain: Case-Based Pharmacology Jeannine M. Brant, PhD, APRN, AOCN Oncology Clinical Nurse Specialist Nurse Scientist Billings Clinic Conflicts of Interest Jeannine Brant has served on the
More informationOpioid Conversion Guidelines
Opioid Conversion Guidelines March 2015 Gippsland Region Palliative Care Consortium Clinical Practice Group Title Keywords Ratified Opioid, Conversion, Drug, Therapy, Palliative, Guideline, Palliative,
More informationSession VI. SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education. Presenter Disclosure Information. Presenting Faculty
Presenter Disclosure Information SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4:15 5pm Getting the Most Clinical Insights from Specific ER/LA Product Information Sources SPEAKERS
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationComedy of Errors: Methadone and Buprenorphine
Comedy of Errors: Methadone and Buprenorphine Douglas Gourlay MD, MSc, FRCP(C), DFASAM Disclosures Nothing to disclosure 2 1 Learning Objectives Explain the pharmacology of methadone and buprenorphine
More informationDemystifying Opioid Conversion Calculations
Demystifying Opioid Conversion Calculations Stephanie Cheng, PharmD, MPH, BCGP Clinical Pharmacist Hospice Pharmacy Solutions November 28, 2018 Learning Objectives After this presentation, you should be
More informationINITIATING THERAPY, MODIFYING DOSING, & DISCONTINUING USE OF ER/LA OPIOID ANALGESICS
INITIATING THERAPY, MODIFYING DOSING, & DISCONTINUING USE OF ER/LA OPIOID ANALGESICS Unit II R. Corey Waller, MD, MS, FACEP Disclosure of Relevant Financial Relationships Content of Activity: ASAM Medical
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More informationProposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)
Proposed Changes to Existing Measure for HEDIS 1 2020: Use of Opioids at High Dosage (UOD) NCQA seeks comments on proposed revisions to the Use of Opioids at High Dosage HEDIS measure. The current measure
More information9/30/15. Learning Objectives. Conflict of Interest. Learning Objectives. Need For Balance. Public Health Issue
Strategies for Safe Opioid Prescribing: Re-Calibrating the Pendulum Swing Traci White, PharmD, PhC Assistant Professor, UNM College of Pharmacy Pharmacist Clinician, Mesilla Valley Hospice tmwhite@nmsu.edu
More informationStrategies for Safe Opioid Prescribing: Re-Calibrating the Pendulum Swing
Strategies for Safe Opioid Prescribing: Re-Calibrating the Pendulum Swing Traci White, PharmD, PhC Assistant Professor, UNM College of Pharmacy Pharmacist Clinician, Mesilla Valley Hospice tmwhite@nmsu.edu
More informationConversion chart from fentanyl to opana er
Conversion chart from fentanyl to opana er (e.g., Nucynta). Both opioid products involved in conversion are one of the following: morphine, oxycodone, oxymorphone, hydromorphone (not extended- release),
More informationMorphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More informationNucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta Page: 1 of 7 Last Review Date: March 18, 2016 Nucynta Description Nucynta IR/ Nucynta
More informationOpioids, Extended Release (ER) Quantity Limit Criteria Program Summary
Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary This program applies to Commercial, GenPlus, NetResults A series, Netresults F series and Health Insurance Marketplace. Belbuca is
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationBJF Acute Pain Team Formulary Group
Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution
More informationFentanyl patch 50 equals what
Search Search Fentanyl patch 50 equals what A drug test is a technical analysis of a biological specimen, for example urine, hair, blood, breath, sweat, and/or oral fluid/saliva to determine the presence
More informationDose equivalent of fentanyl patch to oxycontin
Dose equivalent of fentanyl patch to oxycontin 10-3-2018 Detailed dosage guidelines and administration information for OxyContin (oxycodone hydrochloride). Includes dose adjustments, warnings and precautions.
More informationTransdermal and Parenteral Fentanyl Dosage Calculations and Conversions
Transdermal and Parenteral Fentanyl Dosage Calculations and Conversions Chapter 5 Objectives After reading this chapter and completing all practice problems, the participant will be able to: 1. Describe
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next
More informationOxycontin to ms contin conversion chart
Oxycontin to ms contin conversion chart The Pink, One-Piece Wrap Style 1 ( Pink Stripe) Size - Small - Medium - Large Length (neck to base of tail) - 10 inches - 14 inches - 20 inches Width (without side.
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2099-5 Program Prior Authorization/Medical Necessity Buprenorphine Products (Pain Indications) Medication Belbuca (buprenorphine
More informationOST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO
OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.
More informationCDC Guideline for Prescribing Opioids for Chronic Pain
National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug
More informationOpioid Analgesics. Recommended starting dose for opioid-naïve patients
Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote
More informationCollaboration for REMS Education
Presented by CO*RE Collaboration for Relevant Presented Educationby CO*RE www.core-rems.org Collaboration for REMS Education www.corerems.org Collaborative for REMS Education CO*RE 2014 GENERAL DRUG INFORMATION
More informationANSWER # 1 PHARMACOLOGY. Methadone answers Stoltzfus 4/5/2012 METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017
METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017 Ky Stoltzfus, MD Assistant Professor, Internal Medicine University of Kansas Medical Center ANSWER # 1 Your response might be
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioids, Extended Release (ER) Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioids, Extended Release (ER) Prime Therapeutics will review Prior Authorization
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationLumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes.
Reference Guide for PACU Lumbar Fusion CLINICAL PATHWAY All patient variances to the pathway are to be circled and addressed in the progress notes. This Clinical Pathway is intended to assist in clinical
More informationAnalgesics: Management of Pain In the Elderly Handout Package
Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed
More informationAPPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION
Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION PROVIDER GROUP Pharmacy Opioid Products Indicated for Pain Management MANUAL GUIDELINES All dosage forms
More informationPo dilaudid versus iv dilaudid
Po dilaudid versus iv dilaudid Search IM/IV/SC 120 mg ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic an equianalgesic ratio for PO. Dilaudid official prescribing
More informationPAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationBerkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationConversion from oxycodone to ms contin
Search for: Search Search Conversion from oxycodone to ms contin Opioid Dose Converter. Enter 24-hour total doses below, then click the convert button to display 24-hour equianalgesic. Oxycodone SC. mg.
More informationMorphine er to oxycontin conversion
Morphine er to oxycontin conversion The Borg System is 100 % Morphine er to oxycontin conversion 17-4-2011 Conversion dose from Oxycontin 40mg 3x a day to morphine sulfate 15 mg?. Oxycontin vs morphine
More informationWhat Do You Mean The Morphine Isn t Working? Objectives. Opioid Epidemic. Ellen Fulp, PharmD, BCGP Clinical Education Coordinator AvaCare, Inc.
What Do You Mean The Morphine Isn t Working? Ellen Fulp, PharmD, BCGP Clinical Education Coordinator AvaCare, Inc. 42 nd Annual Hospice & Palliative Care Conference September 2018 Charlotte, NC Objectives
More information2017 Opioid Prescribing Module 401 N. Ewing St. Lancaster, Ohio (740) ~
2017 Opioid Prescribing Module 401 N. Ewing St. Lancaster, Ohio 43130 (740) 687-8000 ~ www.fmchealth.org Introduction The purpose of this module is to reduce the risk of adverse outcomes for adult patients
More informationIntroduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics
Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics In April 2011, FDA announced the elements of a Risk Evaluation and Mitigation Strategy
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationKnock Out Opioid Abuse in New Jersey:
Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids
More information6/6/2018. Nalbuphine: Analgesic with a Niche. Mellar P Davis MD FCCP FAAHPM. Summary of Advantages. Summary of Advantages
Nalbuphine: Analgesic with a Niche Mellar P Davis MD FCCP FAAHPM 1 Summary of Advantages Safe in renal failure- fecal excretion Analgesia equal to morphine with fewer side effects Reduced constipation
More informationNew Guidelines for Opioid Prescribing
New Guidelines for Opioid Prescribing What They Mean for Elders with Chronic Pain Manu Thakral, PhD, ARNP Kaiser Permanente Washington Health Research Institute Kaiser Permanente Washington Health Research
More informationMorphine equivalent calculator suboxone
Morphine equivalent calculator suboxone Gogamz Menu Best Way To Lose 30 Pounds In 6 Months Fat Burner Waist Belt Fat Burn And Target Heart Rate how much weight would i lose calculator Fastest Fat Burner
More informationIntroduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics
Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics In April 2011, FDA announced the elements of a Risk Evaluation and Mitigation Strategy
More information